The Concord Biotech IPO started on August 4, 2023, and ended on August 8, 2023. Shares were allocated on August 11, 2023, and refund processes began on August 14, 2023. On August 17, 2023, the shares were credited to investors demat accounts. Concord Biotech was officially listed on the stock exchange on August 18, 2023.
During the IPO, Concord Biotech offered shares at a price range of ₹705 to ₹741 per share, and the lot size was 20 shares. The total issue size was ₹1551 crores and ₹1551 crores from shares for sale. The IPO was listed on both the NSE and BSE.
Regarding share reservations, 50% of the shares were allocated to Qualified Institutional Buyers (QIB), 15% were reserved for Non-Institutional Investors (NII), and 35% were set aside for retail investors.
Concord Biotech IPO Limited Subscription Update Video
Concord Biotech IPO Subscription Status
The Concord Biotech IPO on August 8, 2023 was subscribed 24.87 times, with the retail category being subscribed 3.78 times, the NII (Non-Institutional Investor) category being subscribed 16.99 times, the QIB (Qualified-Institutional Buyers) category being subscribed 67.67 times and the Employee category being subscribed 24.48 times.
| Category | Subscription |
| QIB | 67.67x |
| NII | 16.99x |
| Retail | 3.78x |
| Employee | 24.48x |
| Total | 24.87x |
Concord Biotech IPO Basic Details
| Company Name | Concord Biotech Limited |
| Domain of Company | Indian Biopharmaceutical Company |
| IPO Open Date | August 4, 2023 |
| IPO Close Date | August 8, 2023 |
| IPO Allotment Date | August 11, 2023 |
| IPO Listing Date | August 18, 2023 |
| Face Value | ₹10 per share |
| Price | ₹705 to ₹741 per share |
| Lot Size | 20 Shares |
| Issue Size | 20,925,652 shares (aggregating up to ₹1,551.00 Cr) |
| Offer for Sale | 20,925,652 shares (aggregating up to ₹1,551.00 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE, BSE |
| Company Promoters | Sudhir Vaid And Ankur Vaid |
About Concord Biotech Limited
Concord Biotech Limited, founded in 1984, is an India-based biopharmaceutical company focused on research and development. With a strong emphasis on fermentation-based APIs in immunosuppressants and oncology, the company has emerged as a prominent global developer and manufacturer with significant market share as of 2022.
With a widespread presence, Concord Biotech supplies its products to more than 70 countries, including major markets like the USA, India, Europe, and Japan.
The company’s expertise lies in manufacturing Active Pharmaceutical Ingredients (API) using fermentation and semi-synthetic processes, as well as producing finished formulations. Starting from a single product, Concord Biotech has evolved into a comprehensive solution provider.
Concord Biotech’s diverse product range covers therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals, and others, attracting customers worldwide. Additionally, the company boasts a robust pipeline of products currently in development.
Concord Biotech IPO Should you subscribe?
Concord Biotech IPO More Details Click Here
Concord Biotech IPO FAQs
What is the start and end date of Concord Biotech IPO Subscription?
The Concord Biotech IPO started on August 4, 2023, and ended on August 8, 2023.
When does Concord Biotech IPO Subscription open?
The Concord Biotech IPO open on August 4, 2023.
When does Concord Biotech IPO Subscription close?
The Concord Biotech IPO Close on August 8, 2023.
What is the allotment date of Concord Biotech IPO?
The allotment date for Concord Biotech IPO is August 11, 2023.
When is the initial refund date of Concord Biotech IPO?
The initial Refund date for Concord Biotech IPO is August 14, 2023.
When were the shares credited to investors demat accounts for the Concord Biotech IPO?
The shares for the Concord Biotech IPO were credited to investors demat accounts on August 17, 2023.
When will Concord Biotech IPO be listed on the stock market?
Concord Biotech IPO stock market will be listed on August 18, 2023 at 10 am.
What was the price range of the Concord Biotech IPO shares?
The Concord Biotech IPO shares were offered at a price range of ₹705 to ₹741 per share.
What was the lot size for the Concord Biotech IPO shares?
The lot size for the Concord Biotech IPO shares was 20 shares.
What was the total issue size of the Concord Biotech IPO?
The total issue size of the Concord Biotech IPO was ₹1551 crores.
How were the shares allocated among different types of investors for the Concord Biotech IPO?
50% of the shares were allocated to Qualified Institutional Buyers (QIB), 15% were reserved for Non-Institutional Investors (NII), and 35% were set aside for retail investors.
On which stock exchanges was the Concord Biotech IPO listed?
The Concord Biotech IPO was listed on both the NSE and BSE.
What is the Concord Biotech IPO Subscription Status?
Concord Biotech IPO is subscribed 00 Times.
